Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 5Phase EARLY_PHASE1 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 172Neoplasms 167Colorectal Neoplasms 154Neoplasm Metastasis 127Melanoma 119Recurrence 116Prostatic Neoplasms 116Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 113Ovarian Neoplasms 110Multiple Myeloma 103Lung Neoplasms 95Stomach Neoplasms 89Squamous Cell Carcinoma of Head and Neck 82Triple Negative Breast Neoplasms 81Glioblastoma 81Lymphoma 76Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 64Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 57Small Cell Lung Carcinoma 54Sarcoma 52Uterine Cervical Neoplasms 51Myelodysplastic Syndromes 51Advanced Solid Tumors 49

Interventions

spartalizumab 1pembrolizumab 1Injections 1Gemcitabine 1Fluorouracil 1Drug Therapy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Malignant Tumors × 1 year × Clear all
NCT05779163 2026-05-14

A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
26 enrolled

Advanced Malignant Tumors

NCT05229497 2026-03-09

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Akeso

Phase 1/2 Active not recruiting
154 enrolled

Advanced Malignant Tumors

NCT05214482 2026-03-03

A Study of AK112 in Advanced Malignant Tumors

Akeso

Phase 1/2 Completed
154 enrolled

Advanced Malignant Tumors

NCT05223231 2026-02-02

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
26 enrolled

Advanced Malignant Tumors

NCT06877650 2026-01-29

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

Shanghai JMT-Bio Inc.

Phase 1/2 Recruiting
436 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡